News

The company said that the filing of the new drug application (NDA) indicates that the registration package is sufficiently complete to allow for a thorough review of the

TAP molecules are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without TAP, there are no cancer markers, so the

Ron Najafi, chairman and CEO of NovaBay, said: “We are very pleased to have received rapid clearance of this important investigational new drug application (IND), as this enables

The purchase price to be paid to Hologic as a result of the transaction is $82 million in cash, $7.5 million of which is payable at the closing

The commission has initiated a two-part study of pharmaceutical distribution channels in December 2006. The first part of the study, dealing with safe medicines in parallel trade, was

The company will use the proceeds from the financing for continued development of ClearPath, the company’s breast brachytherapy device, as well as working capital. Three Arch Partners led

Under the terms of the agreement, Forest will pay Novexel an upfront license payment of E75 million. Forest will fund development and commercialization of the ceftaroline/NXL 104 combination.

The collaboration will utilize Aureon’s integrated systems pathology approach, whereby data generated from tissue morphometry, multiplexed-protein biomarkers, and in situ RNA expression are integrated with patient clinical information

ImaRx intends to transfer the manufacturing process and NDA to Microbix creating a new source for urokinase. This new supply of urokinase will allow ImaRx to continue to